{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:30Z","timestamp":1790369970535,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00520-026-11079-x","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:49:09Z","timestamp":1787327349000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Best available evidence for the management of oxaliplatin-induced hypersensitivity reactions, with implications for hepatic arterial infusion chemotherapy (HAIC)"],"prefix":"10.1007","volume":"34","author":[{"given":"Wanqing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"11079_CR1","doi-asserted-by":"publisher","unstructured":"Zhu D-X RL, Xu J-M (2023) Chinese guidelines for the diagnosis and comprehensive treatment of colorectal cancer liver metastasis (2023 edition). J Digest Oncol (Electronic Edition) 15:86\u201399. https:\/\/doi.org\/10.19538\/j.cjps.issn1005-2208.2023.01.03","DOI":"10.19538\/j.cjps.issn1005-2208.2023.01.03"},{"key":"11079_CR2","unstructured":"China NHCotPsRo (2024) Guidelines for the diagnosis and treatment of primary liver cancer (2024 edition). Electron J Integr Onco 10:17\u201368. https:\/\/kns.cnki.net\/kcms2\/article\/abstract?v=wYvQo-F_OPbbRJvDK_csRt0Jx1OegB2J0-VxktUQdBkDksGBltLHH6UHYTJRbm7ZDcIhZFEPiB2HS3mRyJwYFYdEjENBSlkaFPfbaxvZK-xtvkn7kefLierm0HEE9X43cXrEy4la1hgIStylxh2h-okHbnMWwe3umRLenpKeuRQ=&uniplatform=NZKPT"},{"key":"11079_CR3","unstructured":"FDA. Oxaliplatin: Drug information. 2018.  http:\/\/167.99.184.127\/d\/topic.htm?path=oxaliplatin-drug-information. Accessed 9 Mar 2025"},{"key":"11079_CR4","unstructured":"(NMPA) NMPA (2021) Announcement on revising the package inserts of oxaliplatin preparations (No. 102, 2021). https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypshmshxdgg\/20210824161553124.html. Accessed 9 Mar 2025"},{"key":"11079_CR5","doi-asserted-by":"publisher","unstructured":"Barbin F, Ghidini M, Panichi A et al (2022) Oxaliplatin-related hypersensitivity reactions: a single institution series and literature review. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10123275","DOI":"10.3390\/biomedicines10123275"},{"key":"11079_CR6","doi-asserted-by":"publisher","unstructured":"Pagani M, Bavbek S, Alvarez-Cuesta E et al (2022) Hypersensitivity reactions to chemotherapy: an EAACI Position Paper. Allergy 77:388\u2013403. https:\/\/doi.org\/10.1111\/all.15113","DOI":"10.1111\/all.15113"},{"key":"11079_CR7","doi-asserted-by":"publisher","unstructured":"Muraro A, Worm M, Alviani C et al (2022) EAACI guidelines: Anaphylaxis (2021 update). Allergy 77:357\u2013377. https:\/\/doi.org\/10.1111\/all.15032","DOI":"10.1111\/all.15032"},{"key":"11079_CR8","doi-asserted-by":"publisher","unstructured":"Shaker MS, Wallace DV, Golden DBK et al (2020) Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol 145:1082\u2013123.https:\/\/doi.org\/10.1016\/j.jaci.2020.01.017","DOI":"10.1016\/j.jaci.2020.01.017"},{"issue":"2","key":"11079_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.anai.2023.09.015","volume":"132","author":"DBK Golden","year":"2023","unstructured":"Golden DBK, Wang J, Waserman S, Akin C, Campbell RL, Ellis AK et al (2023) Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol 132(2):124\u2013176. https:\/\/doi.org\/10.1016\/j.anai.2023.09.015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"11079_CR10","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ueg2.12554","volume":"12","author":"JJ Chen","year":"2024","unstructured":"Chen JJ, Jin ZC, Zhong BY et al (2024) Locoregional therapies for hepatocellular carcinoma: the current status and future perspectives. United Eur Gastroenterol J 12:226\u2013239. https:\/\/doi.org\/10.1002\/ueg2.12554","journal-title":"United Eur Gastroenterol J"},{"key":"11079_CR11","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1001\/jamaoncol.2019.4052","volume":"5","author":"LJ Palmieri","year":"2019","unstructured":"Palmieri LJ, Dermine S, Coriat R (2019) Potential areas of interest in a trial of sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for hepatocellular carcinoma. JAMA Oncol 5:1805\u20131806. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4052","journal-title":"JAMA Oncol"},{"key":"11079_CR12","doi-asserted-by":"publisher","first-page":"1544061","DOI":"10.3389\/fonc.2025.1544061","volume":"15","author":"H Ou","year":"2025","unstructured":"Ou H, Li X, Chang S et al (2025) Advances in hepatic arterial perfusion chemotherapy for hepatic metastases. Front Oncol 15:1544061. https:\/\/doi.org\/10.3389\/fonc.2025.1544061","journal-title":"Front Oncol"},{"key":"11079_CR13","unstructured":"Zhu F-YCH, Hua Y-Q et al (2014) Clinical analysis of oxaliplatin-induced hypersensitivity reactions during hepatic arterial infusion for primary liver cancer. Tumor 34:547\u20139+63"},{"key":"11079_CR14","first-page":"2461","volume":"14","author":"Q Song","year":"2022","unstructured":"Song Q, Cai Y, Guo K et al (2022) Risk factors for oxaliplatin-induced hypersensitivity reaction in patients with colorectal cancer. Am J Transl Res 14:2461\u20132468","journal-title":"Am J Transl Res"},{"key":"11079_CR15","unstructured":"Association CA-CACoCTECPCotFA-C (2024) Chinese expert consensus on full-course management of oxaliplatin-induced hypersensitivity reactions (2024 edition). Chin J Cancer 34:785\u2013806"},{"key":"11079_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111767","volume":"130","author":"B Liu","year":"2024","unstructured":"Liu B, Gao S, Guo J et al (2024) High-dose oxaliplatin induces severe hypersensitivity reactions and high recurrence rates during rechallenge in patients treated with hepatic arterial infusion chemotherapy. Int Immunopharmacol 130:111767. https:\/\/doi.org\/10.1016\/j.intimp.2024.111767","journal-title":"Int Immunopharmacol"},{"key":"11079_CR17","unstructured":"NICE. National Institute for Health and Care Excellence.  https:\/\/www.nice.org.uk\/. Accessed 9 Mar 2025"},{"key":"11079_CR18","unstructured":"RNAO. Registered Nurses\u2019 Association of Ontario  https:\/\/rnao.ca\/bpg\/guidelines. Accessed 9 Mar 2025"},{"key":"11079_CR19","unstructured":"SIGN. Scottish Intercollegiate Guidelines Network  https:\/\/www.sign.ac.uk\/. Accessed 9 Mar 2025"},{"key":"11079_CR20","first-page":"56","volume":"25","author":"XZF Cong","year":"2025","unstructured":"Cong XZF, Hao Y-F, Yao X-M (2025) AGREE II guideline appraisal tool: supplementary explanation and interpretation of domain scoring. Journal of Nursing 25:56\u201358","journal-title":"Journal of Nursing"},{"key":"11079_CR21","doi-asserted-by":"publisher","unstructured":"Zhou Y-F HY, Zhu Z et al (2024) JBI Critical Appraisal Checklist for text and opinion papers from the JBI Evidence-Based Healthcare Center. J Nurs Train 39:1075\u201380. https:\/\/doi.org\/10.16821\/j.cnki.hsjx.2024.10.012","DOI":"10.16821\/j.cnki.hsjx.2024.10.012"},{"key":"11079_CR22","doi-asserted-by":"publisher","unstructured":"Twycross A, Shields L (2008) Content analysis. Paediatr Nurs 20:38. https:\/\/doi.org\/10.7748\/paed.20.6.38.s27","DOI":"10.7748\/paed.20.6.38.s27"},{"key":"11079_CR23","doi-asserted-by":"publisher","unstructured":"Brouwers MC, Kho ME, Browman GP et al (2010) AGREE II: advancing guideline development, reporting and evaluation in health care. Cmaj 182:E839\u201342. https:\/\/doi.org\/10.1503\/cmaj.090449","DOI":"10.1503\/cmaj.090449"},{"key":"11079_CR24","doi-asserted-by":"publisher","unstructured":"Wang C-Q, Hu Y (2015) JBI evidence pre-grading and recommendation level system (2014 edition). J Nurs Train 30:964\u20137. https:\/\/doi.org\/10.16821\/j.cnki.hsjx.2015.11.002","DOI":"10.16821\/j.cnki.hsjx.2015.11.002"},{"key":"11079_CR25","doi-asserted-by":"publisher","unstructured":"Salehi T, Seyedfatemi N, Mirzaee MS et al (2021) Nurses\u2019 knowledge, attitudes, and practice in relation to pharmacovigilance and adverse drug reaction reporting: a systematic review. Biomed Res Int 2021:6630404. https:\/\/doi.org\/10.1155\/2021\/6630404","DOI":"10.1155\/2021\/6630404"},{"key":"11079_CR26","doi-asserted-by":"publisher","unstructured":"Kim JH, Jung MK (2025) Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer. J Oncol Pharm Pract 31:17\u201321. https:\/\/doi.org\/10.1177\/10781552231220542","DOI":"10.1177\/10781552231220542"},{"key":"11079_CR27","doi-asserted-by":"publisher","unstructured":"Brockow K, Wurpts G, Trautmann A et al (2023) Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Dermatological Society (DDG), the Association of German Allergologists (\u00c4DA), the German Society for Pediatric Allergology (GPA), the German Contact Dermatitis Research Group (DKG), the German Society for Pneumology (DGP), the German Society of Otorhinolaryngology, Head and Neck Surgery, the Austrian Society of Allergology and Immunology (\u00d6GAI), the Austrian Society of Dermatology and Venereology (\u00d6GDV), the German Academy of Allergology and Environmental Medicine (DAAU), and the German Documentation Center for Severe Skin Reactions (dZh). Allergol Select 7:122\u201339. https:\/\/doi.org\/10.5414\/alx02422e","DOI":"10.5414\/alx02422e"},{"key":"11079_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2174\/0115748863276456231016062628","volume":"19","author":"RA Putri","year":"2024","unstructured":"Putri RA, Ikawati Z, Rahmawati F et al (2024) An awareness of pharmacovigilance among healthcare professionals due to an underreporting of adverse drug reactions issue: a systematic review of the current state, obstacles, and strategy. Curr Drug Saf 19:317\u2013331. https:\/\/doi.org\/10.2174\/0115748863276456231016062628","journal-title":"Curr Drug Saf"},{"key":"11079_CR29","doi-asserted-by":"publisher","unstructured":"Silver J, Garcia-Neuer M, Lynch DM et al (2020) Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin. J Allergy Clin Immunol Pract 8:1668\u201380.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.02.013","DOI":"10.1016\/j.jaip.2020.02.013"},{"key":"11079_CR30","doi-asserted-by":"publisher","unstructured":"Mori Y, Nishimura T, Kitano T et al (2010) Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 79:136\u201343. https:\/\/doi.org\/10.1159\/000320613","DOI":"10.1159\/000320613"},{"key":"11079_CR31","doi-asserted-by":"publisher","unstructured":"Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 24:394\u2013400. https:\/\/doi.org\/10.1200\/jco.2005.03.0106","DOI":"10.1200\/jco.2005.03.0106"},{"key":"11079_CR32","doi-asserted-by":"publisher","unstructured":"Seki K, Senzaki K, Tsuduki Y et al (2011) Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 8:210\u2013215. https:\/\/doi.org\/10.7150\/ijms.8.210","DOI":"10.7150\/ijms.8.210"},{"key":"11079_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2050-6511-15-1","volume":"15","author":"M Parel","year":"2014","unstructured":"Parel M, Ranchon F, Nosbaum A et al (2014) Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol 15:1. https:\/\/doi.org\/10.1186\/2050-6511-15-1","journal-title":"BMC Pharmacol Toxicol"},{"key":"11079_CR34","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.26355\/eurrev_202303_31801","volume":"27","author":"A Selcuk","year":"2023","unstructured":"Selcuk A, Y\u0131ld\u0131z B (2023) Oxaliplatin-induced hypersensitivity reactions: risk factors and management. Eur Rev Med Pharmacol Sci 27:2640\u20132645. https:\/\/doi.org\/10.26355\/eurrev_202303_31801","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"11079_CR35","doi-asserted-by":"publisher","unstructured":"Zhu L, Li H, Du Q et al (2021) Meta-analysis of risk factors associated with oxaliplatin hypersensitivity reactions in cancer patients. Int J Clin Oncol 26:2194\u2013204. https:\/\/doi.org\/10.1007\/s10147-021-02034-3","DOI":"10.1007\/s10147-021-02034-3"},{"key":"11079_CR36","doi-asserted-by":"publisher","unstructured":"Wheatley LM, Plaut M, Schwaninger JM et al (2015) Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol 136:262\u201371.e2. https:\/\/doi.org\/10.1016\/j.jaci.2015.05.027","DOI":"10.1016\/j.jaci.2015.05.027"},{"key":"11079_CR37","doi-asserted-by":"publisher","unstructured":"Vyskocil J, Tucek S, Kiss I et al (2019) Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening. Int Immunopharmacol 74:105728. https:\/\/doi.org\/10.1016\/j.intimp.2019.105728","DOI":"10.1016\/j.intimp.2019.105728"},{"key":"11079_CR38","doi-asserted-by":"publisher","unstructured":"Tanaka M, Komuro M, Kojima Y et al (2025) Usefulness of hydrocortisone prophylaxis for oxaliplatin-induced hypersensitivity reactions: a retrospective study. J Oncol Pharm Pract: 10781552251372177. https:\/\/doi.org\/10.1177\/10781552251372177","DOI":"10.1177\/10781552251372177"},{"key":"11079_CR39","doi-asserted-by":"publisher","unstructured":"ALMuhizi F, De Las Vecillas Sanchez L, Gilbert L et al (2022) Premedication protocols to prevent hypersensitivity reactions to chemotherapy: a literature review. Clin Rev Allergy Immunol 62:534-47. https:\/\/doi.org\/10.1007\/s12016-022-08932-2","DOI":"10.1007\/s12016-022-08932-2"},{"key":"11079_CR40","doi-asserted-by":"publisher","unstructured":"Barrett C, Park SJ, Edmondson L et al (2022) Incidence of hypersensitivity reactions in patients on H1-receptor antagonists receiving oxaliplatin-based chemotherapy. J Oncol Pharm Pract 28:577\u201381. https:\/\/doi.org\/10.1177\/10781552211003958","DOI":"10.1177\/10781552211003958"},{"key":"11079_CR41","doi-asserted-by":"publisher","unstructured":"Jimenez-Rodriguez TW, de Las Vecillas L, Labella M et al (2024) Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes, and management with desensitization. Allergy 79:679\u2013689. https:\/\/doi.org\/10.1111\/all.15940","DOI":"10.1111\/all.15940"},{"key":"11079_CR42","unstructured":"Institute NC. Common terminology criteria for adverse events (CTCAE) version 5.0. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 9 Mar 2025"},{"key":"11079_CR43","doi-asserted-by":"publisher","unstructured":"Robinson M, Greenhawt M, Stukus DR (2017) Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department. Ann Allergy Asthma Immunol 119:164\u2013169. https:\/\/doi.org\/10.1016\/j.anai.2017.06.001","DOI":"10.1016\/j.anai.2017.06.001"},{"key":"11079_CR44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jaip.2014.12.010","volume":"3","author":"S Lee","year":"2015","unstructured":"Lee S, Bellolio MF, Hess EP et al (2015) Time of onset and predictors of biphasic anaphylactic reactions: a systematic review and meta-analysis. J Allergy Clin Immunol Pract 3:408\u201316.e1-2. https:\/\/doi.org\/10.1016\/j.jaip.2014.12.010","journal-title":"J Allergy Clin Immunol Pract"},{"key":"11079_CR45","doi-asserted-by":"publisher","unstructured":"Cardona V, Ansotegui IJ, Ebisawa M et al (2020) World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 13:100472. https:\/\/doi.org\/10.1016\/j.waojou.2020.100472","DOI":"10.1016\/j.waojou.2020.100472"},{"key":"11079_CR46","doi-asserted-by":"publisher","unstructured":"Shaker M, Wallace D, Golden DBK et al (2019) Simulation of health and economic benefits of extended observation of resolved anaphylaxis. JAMA Netw Open 2:e1913951. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.13951","DOI":"10.1001\/jamanetworkopen.2019.13951"},{"key":"11079_CR47","doi-asserted-by":"publisher","unstructured":"Alqurashi W, Ellis AK (2017) Do corticosteroids prevent biphasic anaphylaxis? J Allergy Clin Immunol Pract 5:1194\u20131205. https:\/\/doi.org\/10.1016\/j.jaip.2017.05.022","DOI":"10.1016\/j.jaip.2017.05.022"},{"key":"11079_CR48","doi-asserted-by":"publisher","unstructured":"Campbell DE (2019) Anaphylaxis management: time to re-evaluate the role of corticosteroids. J Allergy Clin Immunol Pract 7:2239\u201340. https:\/\/doi.org\/10.1016\/j.jaip.2019.07.005","DOI":"10.1016\/j.jaip.2019.07.005"},{"key":"11079_CR49","doi-asserted-by":"publisher","unstructured":"Aliyu UM, Okwonna CO (2021) Delayed hypersensitivity to oxaliplatin in a Nigerian patient with colorectal cancer-a case report. J Oncol Pharm Pract 27:1258\u20131260.  https:\/\/doi.org\/10.1177\/1078155220970631","DOI":"10.1177\/1078155220970631"},{"key":"11079_CR50","doi-asserted-by":"publisher","unstructured":"Rogers BB, Cuddahy T, Briscella C et al (2019) Oxaliplatin: detection and management of hypersensitivity reactions. Clin J Oncol Nurs 23:68\u201375. https:\/\/doi.org\/10.1188\/19.Cjon.68-75","DOI":"10.1188\/19.Cjon.68-75"},{"key":"11079_CR51","doi-asserted-by":"publisher","unstructured":"Hadi MA, Neoh CF, Zin RM et al (2017) Pharmacovigilance: pharmacists\u2019 perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract 6:91\u201398. https:\/\/doi.org\/10.2147\/iprp.S105881","DOI":"10.2147\/iprp.S105881"},{"key":"11079_CR52","doi-asserted-by":"publisher","unstructured":"Sultana J, Cutroneo P, Trifir\u00f2 G (2013) Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 4:S73\u20137. https:\/\/doi.org\/10.4103\/0976-500x.120957","DOI":"10.4103\/0976-500x.120957"},{"key":"11079_CR53","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s11096-023-01591-z","volume":"45","author":"L Shafei","year":"2023","unstructured":"Shafei L, Mekki L, Maklad E et al (2023) Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework. Int J Clin Pharm 45:801\u2013813. https:\/\/doi.org\/10.1007\/s11096-023-01591-z","journal-title":"Int J Clin Pharm"},{"key":"11079_CR54","doi-asserted-by":"publisher","unstructured":"Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT et al (2013) Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf 36:317\u201328. https:\/\/doi.org\/10.1007\/s40264-013-0058-2","DOI":"10.1007\/s40264-013-0058-2"},{"key":"11079_CR55","doi-asserted-by":"publisher","unstructured":"Khan Z, Karatas Y, Hamid SM (2023) Evaluation of health care professionals\u2019 knowledge, attitudes, practices and barriers to pharmacovigilance and adverse drug reaction reporting: a cross-sectional multicentral study. PLoS One 18:e0285811. https:\/\/doi.org\/10.1371\/journal.pone.0285811","DOI":"10.1371\/journal.pone.0285811"},{"key":"11079_CR56","doi-asserted-by":"publisher","unstructured":"Hayek A, Sridhar SB, Rabbani SA et al (2024) Exploring pharmacovigilance practices and knowledge among healthcare professionals: a cross-sectional multicenter study. SAGE Open Med 12:20503121241249908.https:\/\/doi.org\/10.1177\/20503121241249908","DOI":"10.1177\/20503121241249908"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11079-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11079-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:04:46Z","timestamp":1790366686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11079-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["11079"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11079-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"885"}}